 |
| 31-Jan-14 | Reiterated |
Argus |
Buy |
$130 → $135 |
|
| 20-Nov-13 | Reiterated |
Deutsche Bank |
Buy |
$138 → $142 |
|
| 29-Aug-13 | Reiterated |
UBS |
Buy |
$121 → $124 |
|
| 27-Aug-13 | Reiterated |
Barclays |
Overweight |
$105 → $115 |
|
| 31-Jul-13 | Reiterated |
Oppenheimer |
Perform |
$100 → $109 |
|
| 24-Apr-13 | Reiterated |
Deutsche Bank |
Buy |
$108 → $115 |
|
| 15-Apr-13 | Reiterated |
Barclays |
Equal Weight |
$90 → $105 |
|
| 08-Apr-13 | Reiterated |
RBC Capital Mkts |
Outperform |
$95 → $105 |
|
| 25-Jan-13 | Upgrade |
Argus |
Hold → Buy |
$96 |
|
| 24-Jan-13 | Reiterated |
UBS |
Buy |
$96 → $98 |
|
| 12-Sep-12 | Downgrade |
Robert W. Baird |
Outperform → Neutral |
$84 |
|
| 10-Sep-12 | Upgrade |
UBS |
Neutral → Buy |
$80 → $96 |
|
| 02-Aug-12 | Downgrade |
Argus |
Buy → Hold |
|
|
| 15-Mar-12 | Resumed |
Stifel Nicolaus |
Hold |
|
|
| 09-Feb-12 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 09-Sep-11 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| 10-May-11 | Reiterated |
MP Advisors |
Outperform |
$63 → $65 |
|
| 25-Apr-11 | Reiterated |
Stifel Nicolaus |
Buy |
$70 → $68 |
|
| 21-Apr-11 | Reiterated |
Oppenheimer |
Outperform |
$66 → $63 |
|
| 14-Mar-11 | Initiated |
Standpoint Research |
Buy |
$66 |
|
|
|
| 07-Mar-14 06:31PM | Better Buy: Biogen Or Amgen? at Motley Fool |
| 03:46PM | U.S. FDA asks Sanofi, Regeneron to assess cholesterol drug's cognitive risks Reuters |
| 02:11PM | Regeneron Cholesterol-Drug Worries Ding Stock at Investor's Business Daily |
| 11:01AM | Cancer Immunotherapy Race Stays Unpredictable at Motley Fool |
| 06-Mar-14 08:20PM | In 401(k) Plans, a Little More Makes a Big Difference at BusinessWeek |
| 07:41PM | Are all the shorts dead? at MarketWatch |
| 02:31PM | Better Biotech Buy: Celgene vs. Gilead Sciences at Motley Fool |
| 07:41AM | The Zacks Analyst Blog Highlights: Sanofi, Aegerion Pharmaceuticals, Shire, Amgen and Biogen Idec Zacks |
| 05-Mar-14 08:04PM | Justices May Limit Securities Fraud Suits at New York Times |
| 05:29PM | [video] Believe in strong Europe reimbursement: Dendreon CEO at CNBC |
| 04:41PM | Amgen Announces 2014 Second Quarter Dividend PR Newswire |
| 01:19PM | Profit from Orphan Drugs: 3 Choices Zacks |
| 12:02PM | 3 Drugs Stocks Driving The Industry Higher at TheStreet |
| 04-Mar-14 02:32PM | Best stocks for legalized marijuana at MarketWatch |
| 01:50PM | Myriad Genetics Up on Prolaris Data; Aims Reimbursement Zacks |
| 03-Mar-14 03:12PM | How To Invest In Biotech at Forbes |
| 02:05PM | Biogen Keeps Momenum Going With MS Drug Tecfidera at Investor's Business Daily |
| 02:05PM | Biogen Keeps Momentum Going With MS Drug Tecfidera at Investor's Business Daily |
| 02:05PM | Biogen Idec Keeps Momentum Going With MS Drug Tecfidera at Investor's Business Daily |
| 09:52AM | Are These Biotechs Part of Your Portfolio? Zacks |
| 02-Mar-14 12:39PM | Best stocks for legalized marijuana and more at MarketWatch |
| 01-Mar-14 01:26PM | Amgen To Present At The Cowen And Company 34th Annual Healthcare Conference PR Newswire |
| 08:32AM | Insys Set To Report Q4 Earnings With Stock Surging at Investor's Business Daily |
| 28-Feb-14 01:04PM | AMGEN INC Financials EDGAR Online Financials |
| 27-Feb-14 07:41AM | Zacks Rank #1 Additions for Thursday Zacks |
| 06:00AM | Carolina Confronts Classroom Corruption as Athletes Fail to Read at Bloomberg |
| 12:00AM | Investor Class Actions Seen at Risk in Halliburton Case at Bloomberg |
| 25-Feb-14 06:31PM | Dividend Derby: Bristol-Myers Squibb Vs. AstraZeneca at Motley Fool |
| 04:20PM | Regeneron Chief Leonard Schleifer Becomes A Billionaire After 25 Year Search For New Drugs at Forbes |
| 11:09AM | One Reason the Biotech Boom Won't Turn to Bust at Barrons.com |
| 06:15AM | Update-Moody's: AbbVie, Amgen and Roche most exposed to biosimilar drugs market Reuters |
| 06:06AM | Moody's: AbbVie, Amgen and Roche most exposed to biosimilar drugs market Moody's |
| 24-Feb-14 04:08PM | AMGEN INC Files SEC form 10-K, Annual Report EDGAR Online |
| 21-Feb-14 04:30PM | Amgen To Present At The RBC Capital Markets' Global Healthcare Conference PR Newswire |
| 04:23AM | Don't Underestimate Amgen: Part 2B at Seeking Alpha |
| 20-Feb-14 02:40PM | [video] Best biotech stock plays at CNBC |
| 02:30AM | Bayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases PR Newswire |
| 17-Feb-14 03:16PM | Amgen Increases Dividend 30%, But Is It A Buy? at Seeking Alpha |
| 14-Feb-14 12:01AM | Retirement Hit: Companies From Facebook to JPMorgan Squeeze 401K Plans Bloomberg |
| 12:01AM | Companies Squeeze 401(k) Plans From Facebook to JPMorgan at Bloomberg |
| 12-Feb-14 04:32PM | Can Biogen Idec Crush The Market In 2014? at Motley Fool |
| 02:32PM | Here's How Regeneron Plans to Repeat Eylea's Success at Motley Fool |
| 08:02AM | Illumina, Alexion Lead 4 Big Caps Drawing Big Buyers at Investor's Business Daily |
| 06:50AM | Short Sellers Shy Away From Biotechs at 24/7 Wall St. |
| 06:50AM | Short Sellers Shy Away From Biotechs |
| 11-Feb-14 06:34PM | Amgen Inc's Deep Pipeline Offsets Some of the Price Risk at Motley Fool |
| 09:20AM | Stock Market News for February 11, 2014 Zacks |
| 08:11AM | Yale Study On FDA Approvals -- Informative Or Irresponsible? at Forbes |
| 10-Feb-14 11:04PM | Why You Shouldn't Overlook Amgen, Inc. at Motley Fool |
| 09-Feb-14 07:02AM | Merck Falling Earnings Hide Hidden Potential at Motley Fool |
| 07-Feb-14 09:56PM | 3 Stocks That Absolutely Crushed the Market on Friday -- Here's Why athenahealth inc, Puma Biotechnology Inc, and Cytokinetics, Inc Left Investors Smiling at Motley Fool |
| 06:48PM | Why Wall Street Is Excited about Alexion Pharmaceuticals at Motley Fool |
| 04:09PM | Pharma data play larger role in anti-doping effort AP |
| 04:06PM | Pharma data play larger role in anti-doping effort AP |
| 06-Feb-14 07:15AM | The Zacks Analyst Blog Highlights: Amgen, Biogen, Vertex, Celgene and Alexion Zacks |
| 05-Feb-14 08:18PM | Profit Drops 14% at Merck, Just Below Wall St. Forecast at New York Times |
| 11:48AM | Merck Q4 Misses, But Cancer Deals Ignite Stock at Investor's Business Daily |
| 09:21AM | What to Watch at Amgen, Merck, Pfizer, and Myriad Genetics This Morning at Motley Fool |
| 06:15AM | Amgen And Merck Announce Collaboration To Evaluate Investigational Combination Treatment For Advanced Melanoma PR Newswire |
| 04-Feb-14 07:06PM | Novartis AG: Combating $2 Billion in Lost Sales at Motley Fool |
| 03-Feb-14 06:32PM | Xgeva and Prolia: Setting the Pace for Amgen, Inc. at Motley Fool |
| 05:35PM | 3 Reasons For Biotech Stock Advance To Continue at Investor's Business Daily |
| 02-Feb-14 01:01PM | Can Biotech Dominate for a 4th Year in a Row? |
| 01-Feb-14 08:32AM | Amgen Goes 6 for 6 Fighting Cholesterol at Motley Fool |
| 08:32AM | Amgen Goes 6 for 6 Fighting Cholesterol |
| 31-Jan-14 05:18PM | TetraLogic Pharmaceuticsls And The Chatter About A Cure For Cancer at Seeking Alpha |
| 02:12PM | Biotech Sector Performance January 2014 Strong, but What's Ailing Celgene? at TheStreet |
| 02:12PM | Biotech Sector Performance January 2014 Strong, but What's Ailing Celgene? |
| 02:11PM | Amgens Cholesterol-Fighting Drug Succeeds Yet Again at Wall St. Cheat Sheet |
| 02:11PM | Amgens Cholesterol-Fighting Drug Succeeds Yet Again |
| 11:45AM | Amgen - Focus On Growth And A Full Pipeline Can Continue To Drive Returns at Seeking Alpha |
| 11:45AM | Amgen - Focus On Growth And A Full Pipeline Can Continue To Drive Returns |
| 10:57AM | 2014's Better Biotech Buy: Biogen Idec, Inc. vs. Amgen, Inc. at Motley Fool |
| 10:57AM | 2014's Better Biotech Buy: Biogen Idec, Inc. vs. Amgen, Inc. |
| 30-Jan-14 06:56PM | Amgen Readies Cholesterol Drug After Results From Trial at Bloomberg |
| 06:56PM | Amgen Readies Cholesterol Drug After Results From Trial |
| 05:41PM | Amgen's cholesterol fighter succeeds in 5th late-stage study Reuters |
| 05:41PM | Amgen's cholesterol fighter succeeds in 5th late-stage study |
| 04:39PM | Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial Of Evolocumab (AMG 145) In Patients With Heterozygous Familial Hypercholesterolemia PR Newswire |
| 04:39PM | Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial Of Evolocumab (AMG 145) In Patients With Heterozygous Familial Hypercholesterolemia |
| 08:37AM | Amgen's Earnings Increase 30%, But Is It A Buy? at Seeking Alpha |
| 08:37AM | Amgen's Earnings Increase 30%, But Is It A Buy? |
| 29-Jan-14 08:53PM | Pharma Strength Expected To Continue With Eli Lilly at Seeking Alpha |
| 08:53PM | Pharma Strength Expected To Continue With Eli Lilly |
| 01:45PM | [video] Biotech boom keeps going at CNBC |
| 01:39PM | Boeing Outlook Upstages S&P 500 Earnings Beating Estimate at Bloomberg |
| 12:13PM | Biogen Rises 1.6%; Street Shrugs Off Conservative Guidance at Barrons.com |
| 10:30AM | Another Strong Earnings Beat from Amgen Zacks |
| 07:14AM | Turkey, Facebook and lining up Apple against an unlikely cast at MarketWatch |
| 03:01AM | Don't Underestimate Amgen: Part 2A, Cardiovascular And Oncology Pipeline Products at Seeking Alpha |
| 28-Jan-14 09:33PM | Amgen's CEO Discusses Q4 2013 Results - Earnings Call Transcript Seeking Alpha |
| 08:28PM | Amgen's 4th-quarter profit leaps 30% on higher sales |
| 07:27PM | Amgen 4Q profit leaps 30 percent on higher sales AP |
| 07:17PM | News Summary: Amgen Q4 net jumps on higher sales AP |
| 07:13PM | On the Call: Amgen CEO Bob Bradway AP |
| 06:42PM | Amgen 4Q profit leaps 30 percent on higher sales AP |
| 06:09PM | Amgen profit tops Street expectations; focus on new drugs Reuters |
| 06:08PM | Acquisition and Product Sale Growth Drives Amgen's Q4 Profit Up 30% at Motley Fool |
| 05:18PM | Amgen earnings beat forecasts, but 2014 outlook leaves investors cold at MarketWatch |
| 05:10PM | Amgen Q4 profit leaps 30 percent on higher sales AP |
|
|
| Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| de Carbonnel Francois | Director | Mar 06 | Option Exercise | 54.44 | 10,000 | 544,350 | 25,364 | Mar 07 05:23 PM | | de Carbonnel Francois | Director | Mar 06 | Sale | 126.69 | 1,000 | 126,690 | 18,343 | Mar 07 05:23 PM | | BALTIMORE DAVID | Director | Feb 26 | Option Exercise | 62.55 | 5,000 | 312,750 | 31,879 | Feb 26 08:28 PM | | HENDERSON REBECCA M | Director | Feb 13 | Option Exercise | 62.41 | 20,000 | 1,248,160 | 25,549 | Feb 14 04:34 PM | | HENDERSON REBECCA M | Director | Feb 13 | Sale | 123.53 | 20,000 | 2,470,680 | 5,549 | Feb 14 04:34 PM | | Bradway Robert A | Chairman, CEO and President | Feb 12 | Option Exercise | 62.55 | 65,000 | 4,065,750 | 216,040 | Feb 14 04:19 PM | | AMGEN INC | 10% Owner | Dec 17 | Buy | 7.00 | 272,142 | 1,904,994 | 541,399 | Dec 18 06:09 PM | | Balachandran Madhavan | EVP, Operations | Sep 04 | Option Exercise | 58.43 | 18,000 | 1,051,740 | 59,133 | Sep 05 07:33 PM | | Balachandran Madhavan | EVP, Operations | Sep 04 | Sale | 112.76 | 18,000 | 2,029,768 | 34,851 | Sep 05 07:33 PM | | BALTIMORE DAVID | Director | Aug 28 | Sale | 109.66 | 4,582 | 502,462 | 27,789 | Aug 30 05:36 PM | | Amgen Ventures LLC | 10% Owner | Jun 05 | Buy | 15.00 | 16,666 | 249,990 | 334,126 | Jun 05 04:01 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 22 | Option Exercise | 54.62 | 6,130 | 334,791 | 22,863 | May 24 05:18 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 22 | Sale | 104.78 | 6,130 | 642,296 | 16,733 | May 24 05:18 PM | | Balachandran Madhavan | EVP, Operations | May 21 | Option Exercise | 50.44 | 6,000 | 302,640 | 46,956 | May 21 08:18 PM | | Balachandran Madhavan | EVP, Operations | May 21 | Sale | 103.28 | 6,000 | 619,681 | 34,851 | May 21 08:18 PM | | HENDERSON REBECCA M | Director | May 17 | Option Exercise | 55.76 | 7,000 | 390,310 | 13,898 | May 20 07:15 PM | | HENDERSON REBECCA M | Director | May 17 | Sale | 105.72 | 8,421 | 890,300 | 5,477 | May 20 07:15 PM | | Patton Cynthia M | SVP & CCO | May 16 | Option Exercise | 54.58 | 3,544 | 193,437 | 18,986 | May 17 05:42 PM | | Patton Cynthia M | SVP & CCO | May 16 | Sale | 105.01 | 3,544 | 372,148 | 15,442 | May 17 05:42 PM | | BIONDI FRANK | Director | May 14 | Option Exercise | 56.50 | 10,000 | 564,950 | 39,780 | May 16 05:38 PM | | PELHAM JUDITH C | Director | May 14 | Option Exercise | 55.47 | 25,000 | 1,386,650 | 48,149 | May 16 05:42 PM | | PELHAM JUDITH C | Director | May 14 | Sale | 108.25 | 25,000 | 2,706,165 | 23,149 | May 16 05:42 PM | | BIONDI FRANK | Director | May 14 | Sale | 108.43 | 10,000 | 1,084,318 | 29,780 | May 16 05:38 PM | | de Carbonnel Francois | Director | Apr 30 | Option Exercise | 54.74 | 10,000 | 547,400 | 21,930 | May 02 06:26 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 29 | Option Exercise | 50.44 | 10,000 | 504,400 | 64,643 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 29 | Sale | 107.02 | 10,000 | 1,070,191 | 54,643 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 26 | Option Exercise | 58.43 | 10,000 | 584,300 | 66,077 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 26 | Sale | 107.99 | 10,000 | 1,079,872 | 56,077 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 25 | Option Exercise | 54.69 | 8,662 | 473,725 | 65,973 | Apr 26 05:33 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 25 | Sale | 107.95 | 8,662 | 935,029 | 57,311 | Apr 26 05:33 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 24 | Sale | 105.95 | 6,924 | 733,565 | 58,311 | Apr 26 05:33 PM | | de Carbonnel Francois | Director | Mar 13 | Option Exercise | 54.74 | 10,000 | 547,400 | 17,805 | Mar 14 06:18 PM |
|
|
|
|
|
|
